Comparison · NCT01200238-sae
STA-9090: Cohort A vs STA-9090: Cohort B: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. STA-9090: Cohort A vs STA-9090: Cohort B: serious adverse events. Trial comparisons, record NCT01200238-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01200238-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.286 | 0.0822 | 0.641 | wilson | |
| Risk in group 2 | 0.9 | 0.596 | 0.982 | wilson | |
| Risk difference, group 1 minus group 2 | -0.614 | -0.834 | -0.147 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.317 | 0.0966 | 1.04 | log | |
| Odds ratio, group 1 over group 2 | 0.0444 | 0.00318 | 0.621 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on STA-9090: Cohort A than on STA-9090: Cohort B | 1.63 | 1.2 | 6.82 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | STA-9090: Cohort A | Cohort A participants received STA-9090 200 mg/m2 given intravenously (IV) over 1 hour once weekly (d1, 8, 15 of a 28 day cycle).~Participants were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal. | 2 | 7 | EG000 |
| Group 2 | STA-9090: Cohort B | Cohort B participants received STA-9090 150 mg/m2 given intravenously over 1 hour (IV) twice weekly (d1, 4, 8, 11, 15, 18 of a 28 day cycle).~Participants were treated until evidence of disease progression, unacceptable toxicity, intercurrent illness or withdrawal. | 9 | 10 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
AE assessment was ongoing from the start of study drug and up to day 30 post-treatment; AEs were assessed for the median treatment duration of 1.8 months for each cohort and up to 12.5m in Cohort A and up to 31.7m in Cohort B and then add the 30 days post-treatment.
Source ClinicalTrials.gov
Trial
- Title
- STA-9090(Ganetespib) in Metastatic Ocular Melanoma
- NCT number
- NCT01200238
- Phases
- PHASE2
- Conditions
- Ocular Melanoma
- Interventions
- STA-9090
- Lead sponsor
- Dana-Farber Cancer Institute
- Results first posted
- 2018-06-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01200238?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01200238-sae